Page last updated: 2024-12-07

benzyloxycarbonyltryptophan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzyloxycarbonyltryptophan (Z-Trp) is a protected amino acid derivative commonly used in peptide synthesis. Its synthesis involves the reaction of tryptophan with benzyl chloroformate under basic conditions. The benzyloxycarbonyl (Z) group acts as a protecting group for the amino group of tryptophan, preventing undesired side reactions during peptide coupling. Z-Trp is important in peptide synthesis as it allows for selective coupling of amino acids to the carboxyl terminus of tryptophan without affecting the side chain indole ring. It is also used in the preparation of various bioactive peptides, such as neuropeptides and hormones. Z-Trp has been studied extensively for its role in the synthesis of biologically active peptides and its potential applications in drug discovery.'

benzyloxycarbonyltryptophan: receptor antagonist for peptides from gastrin family; RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID101176
CHEMBL ID291603
SCHEMBL ID220800
MeSH IDM0132384

Synonyms (50)

Synonym
cbz-l-trp
(s)-2-benzyloxycarbonylamino-3-(1h-indol-3-yl)-propionic acid
bdbm50043807
z-trp-oh
benzyloxycarbonyltryptophan
7432-21-5
z-trp-oh, 97%
n-carbobenzoxy-l-tryptophan
n-cbz-l-tryptophan
n-cbz-dl-tryptophan
CHEMBL291603 ,
(2s)-3-(1h-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoic acid
STK921980
n-[(benzyloxy)carbonyl]-l-tryptophan
(2s)-2-{[(benzyloxy)carbonyl]amino}-3-(1h-indol-3-yl)propanoic acid
nsc 521831
einecs 231-074-4
n-benzyloxycarbonyl-l-tryptophan
l-tryptophan, n-[(phenylmethoxy)carbonyl]-
AKOS005175156
BP-13290
z-l-trp-oh
SCHEMBL220800
(s)-2-(((benzyloxy)carbonyl)amino)-3-(1h-indol-3-yl)propanoic acid
DTXSID00225332
nalpha-benzyloxycarbonyl-l-tryptophan
(s)-n-benzyloxycarbonyl-l-tryptophan
nalpha -benzyloxycarbonyl-l-tryptophan
cbz-trp-oh
cbz-l-trp-oh
n-[(phenylmethoxy)carbonyl]-l-tryptophan
n-carbobenzoxyltryptophan
W-104421
n-[(benzyloxy)carbonyl]tryptophan #
n-cbz-tryptophane
n(alpha)-cbz-l-tryptophan
mfcd00065700
n-alpha-benzyloxycarbonyl-l-tryptophane
M03036
AC-8577
nalpha-cbz-l-tryptophan
(s)-2-(benzyloxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid
n-a-z-l-tryptophan
AS-12754
((benzyloxy)carbonyl)-l-tryptophan
AC1012
tryptophan, n-[(phenylmethoxy)carbonyl]-
((BENZYLOXY)CARBONYL)TRYPTOPHAN
CS-W011913
EN300-121297
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Stromelysin-1Homo sapiens (human)IC50 (µMol)5.00000.00001.148410.0000AID208196; AID208197
Stromelysin-1Homo sapiens (human)Ki4.20000.00030.54258.0000AID208322; AID208323
Substance-P receptorCavia porcellus (domestic guinea pig)IC50 (µMol)2.50000.00002.751810.0000AID208197
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1148052Antineoplastic activity against mouse EAC allografted in CF1 mouse assessed as packed cell volume on day 7 measured at 33 mg/kg (Rvb = 32.75 +/- 7.87%)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID208196Inhibition of recombinant full length stromelysin (FLS).1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors.
AID1148054Antineoplastic activity against mouse EAC allografted in CF1 mouse assessed as tumor growth inhibition on day 7 measured at 33 mg/kg1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID208323Inhibition of recombinant stromelysin catalytic domain (SCD)1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors.
AID1148053Antineoplastic activity against mouse EAC allografted in CF1 mouse assessed as ascites volume on day 7 measured at 33 mg/kg (Rvb = 4.1 +/- 1.24 mL)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID208322Inhibition of recombinant full length stromelysin (FLS)1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors.
AID208197In vitro inhibition of recombinant stromelysin catalytic domain.1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors.
AID1148051Antineoplastic activity against mouse EAC allografted in CF1 mouse assessed as animal survival on day 7 measured at 33 mg/kg1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (50.00)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.44 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]